Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.

导出 OA

翻译打印收藏纠错

作者： Xiwei,Ding ^[1] ; Roongruedee,Chaiteerakij ^[2] ; Catherine D,Moser ^[3] ; Hassan,Shaleh ^[3] ; Jeffrey,Boakye ^[3] ; Gang,Chen ^[3] ; Albert,Ndzengue ^[3] ; Ying,Li ^[3] ; Yanling,Zhou ^[3] ; Shengbing,Huang ^[3] ; Frank A,Sinicrope ^[3] ; Xiaoping,Zou ^[4] ; Melanie B,Thomas ^[5] ; Charles D,Smith ^[6] ; Lewis R,Roberts ^[3]

作者单位： Department of Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.;Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA. ^[1] Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA.;Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. ^[2] Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA. ^[3] Department of Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. ^[4] Hollings Cancer Center, Division of Hematology-Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. ^[5] Apogee Biotechnology Corporation, Hummelstown, PA, USA. ^[6]

关键词 ABC294640 autophagy cholangiocarcinoma sorafenib sphingosine kinase 2